Amerikanische Gesellschaft für Hirudotherapie

Thyroid Eye Disease (Investigational Periocular Adjunct)

Highly investigational periocular adjunct for stable thyroid eye disease; ocular risk is critical; teprotumumab and orbital decompression remain primary.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for thyroid eye disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). Anecdotal periocular reports only. Evidence-based first-line management is smoking cessation (critical), optimization of thyroid function, selenium supplementation in mild active disease, intravenous methylprednisolone for moderate-to-severe active disease, teprotumumab for active moderate-to-severe TED, orbital radiotherapy in select cases, and surgical orbital decompression for vision-threatening or quiescent severe disease.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Periocular bleeding, eyelid hematoma, or conjunctival bleeding (vision-threatening in active TED with proptosis)
  • Worsening of corneal exposure if eyelid swelling temporarily increases
  • Increased intraorbital pressure — theoretical risk to optic nerve in compressive TED
Wer dies nicht in Betracht ziehen sollte
  • Patients with active vision-threatening TED (optic neuropathy, severe corneal exposure) — needs urgent IV steroids or surgery
  • Patients still smoking — smoking cessation alone often improves TED course substantially
  • Patients who have not had endocrine workup to confirm euthyroid status
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
Was Sie Ihren Kliniker fragen sollten
  • Have I had a full TED workup with an oculoplastic surgeon or endocrinologist?
  • Is my thyroid hormone level optimized and have I stopped smoking?
  • Am I a candidate for teprotumumab or IV methylprednisolone?
  • What is the published periocular leech-therapy safety record?
  • Who specifically will manage any bleeding or eyelid hematoma?
  • How will optic nerve function be monitored during the course?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Vision change of any kind — blurriness, color desaturation, dimness, or loss
  • Severe eye pain, especially with eye movement
  • Sudden inability to close the eye completely or new double vision

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for thyroid eye disease — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace teprotumumab, IV methylprednisolone, orbital decompression, or other proven TED treatments.
  • It does not change the underlying autoimmune process driving TED.
  • It does not address smoking, which is the single strongest modifiable TED risk factor.
  • It does not have controlled-trial evidence and carries periocular risks.

Clinical Profile

Category
ophthalmologic
ICD-10
H06.2, E05.00
Safety tier
high

Evidence Summary

Thyroid eye disease (Graves orbitopathy) management follows EUGOGO 2021 guidelines: euthyroid status maintenance, smoking cessation, selenium for mild disease, teprotumumab (IGF-1R inhibitor, FDA-approved 2020) or intravenous methylprednisolone for moderate-severe active disease, and orbital decompression in the chronic stage. No controlled clinical trial of leech therapy for thyroid eye disease has been published; use is investigational and mechanistic only. Any proposed local antiinflammatory or lymphatic-drainage rationale for periocular application is theoretical and unsupported by clinical evidence, so the honest evidence grade is D. Periocular leech application carries serious ocular-risk safety concerns, including corneal exposure and infection adjacency, and active TED is an absolute exclusion.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Wollina U (2006)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active thyroid eye disease (CAS ≥3)
  • Optic neuropathy or vision-threatening disease
  • Corneal exposure or active keratitis
  • Uncontrolled hyperthyroidism
  • Recent teprotumumab or IV methylprednisolone (<3 months)
  • Any direct periocular placement

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Thyroid Eye Disease (Investigational Periocular Adjunct) — Hirudotherapy Evidence | ASH